Výsledky vyhledávání - "V. Sorotskaya"

AB0928 CHARACTERISTICS OF AXIAL PSORIATIC ARTHRITIS PATIENTS WITH SYMMETRICAL AND ASYMMETRICAL SACROILIITIS

Autor: E. Gubar, T. Korotaeva, Y. Korsakova, E. Loginova, L. Vorobyova, S. Glukhova, E. Nasonov, V. Sorotskaya, I. Kushnir, I. Shchendrigin, I. Umnova, P. Shesternya

Publikováno v: Annals of the Rheumatic Diseases. 81:1592.2-1593

BackgroundThe latest data show that psoriatic arthritis (PsA) patients (pts) with asymmetrical sacroiliitis (SI) have clinical and genetic features which are considered typical for PsA (1).ObjectivesTo analyze comparative clinical characteristics of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e1f9eb3c31c3e78466ff7cae0bef4e05
https://doi.org/10.1136/annrheumdis-2022-eular.1589

Zobrazit plný text záznamu

POS1082 CHARACTERISTICS OF PSORIATIC ARTHRITIS (PSA) PATIENTS WITH ENTHESITIS. DATA FROM RUSSIAN PSA REGISTRY (RU-PSART)

Autor: E. Loginova, T. Korotaeva, E. Gubar, Y. Korsakova, S. Glukhova, E. Nasonov, V. Sorotskaya, I. Patrikeeva, P. Shesternya, I. Shchendrigin

Publikováno v: Annals of the Rheumatic Diseases. 81:867-867

BackgroundPsoriatic arthritis (PsA) is a disease with multidomain clinical presentation such as arthritis, enthesitis, dactylitis, spondylitis and psoriasis (PsO). [1]. Enthesitis is a key clinical feature of PsA with significant impact on function,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0d572071d40a8e6c2f304e5183680e44
https://doi.org/10.1136/annrheumdis-2022-eular.2554

Zobrazit plný text záznamu

POS1090 THE IMPACT OF NUMBER OF COMORBIDITIES ON ACHIEVEMENT REMISSION OR LOW DISEASE ACTIVITY BY DAPSA IN PSORIATIC ARTHRITIS. DATA FROM THE RUSSIAN OBSERVATIONAL COHORT

Autor: Y. Korsakova, E. Gubar, E. Loginova, T. Korotaeva, V. Sorotskaya, I. Patrikeeva, P. Shesternya, I. Umnova, E. Nasonov

Publikováno v: Annals of the Rheumatic Diseases. 81:871.2-872

BackgroundThe goal of psoriatic arthritis (PsA) treatment is achievement remission (REM) or Low Disease Activity (LDA) by DAPSA. The impact of comorbidities, especially obesity, metabolic syndrome on PsA activity and on biological treatment response

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::82a1c46437d63eec00bff4559869bfd9
https://doi.org/10.1136/annrheumdis-2022-eular.3308

Zobrazit plný text záznamu

POS0976 ANALYSIS OF BIOLOGIC THERAPY RETENTION RATE IN PSORIATIC ARTHRITIS PATIENTS WITH AND WITHOUTV AXIAL INVOLVEMENT. DATA FROM CLINICAL PRACTICE

Autor: I. Patrikeeva, Irina Umnova, Svetlana Glukhova, Nasonov El, Elena Loginova, Y. Korsakova, Tatiana Korotaeva, V. Sorotskaya, E. Gubar, N. Kuznetsova

Publikováno v: Annals of the Rheumatic Diseases. 80:754-755

Background:Limited data are available on retention rates of biologic therapy in psoriatic arthritis (PsA) patients (pts) with axial involvement. It has been shown that in the subset of pts with prevalent axial involvement (AS versus PsA and AxSpA ver

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6e7068b7ce09b505095652c2828bfcf4
https://doi.org/10.1136/annrheumdis-2021-eular.2007

Zobrazit plný text záznamu

AB0341 SURVIVAL OF REMISSION OR LOW DISEASE ACTIVITY IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH TOFACITINIB. RESULTS OF RUSSIAN NATIONAL REGISTER

Autor: Alexander Lila, I. M. Marusenko, I. Grabovetskaya, A. Baranov, E. Gaydukova, Nasonov El, V. Sorotskaya, V. Mazurov, T. Salnikova, Galina Lukina, D. Chakieva, Inna Gaydukova, A. R. Babaeva, E. Kalinina, R. Samigullina

Publikováno v: Annals of the Rheumatic Diseases. 79:1469-1470

Background:Tofacitinib is an oral Janus Kinase inhibitor for the treatment of rheumatoid arthritis (RA). The survival of remission or low disease activity (LDA) in RA patients, treated with tofacitinib remain unknown.Objectives:To evaluate the surviv

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::941192d587e76a993966b52691b5e1ae
https://doi.org/10.1136/annrheumdis-2020-eular.4710

Zobrazit plný text záznamu

AB0576 BONE EROSION IN PSORIATIC ARTHRITIS ASSOCIATED WITH PSORIASIS DURATION, SKIN, NAIL AND JOINT DISEASE SEVERITY

Autor: V. Sorotskaya, Nasonov El, N. Kuznetsova, Tatiana Korotaeva, Irina Umnova, M. Chamurlieva, Y. Korsakova, Elena Loginova, I. Shchendrigin, E. Gubar, I. Patrikeeva, Svetlana Glukhova

Publikováno v: Annals of the Rheumatic Diseases. 80:1325.2-1326

Background:Psoriatic arthritis (PsA) is heterogeneous in its clinical presentation and disease course, but many patients (pts) develop a destructive form of arthritis. Psoriasis (PsO) precedes arthritis by an average of 7 years. [1]. Theory of transi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::9541e76d61637ce5b00a7a833b3255d8
https://doi.org/10.1136/annrheumdis-2021-eular.2796

Zobrazit plný text záznamu

AB0135 A VERY EARLY CLINICAL RESPONSE TO TOFACITINIB IS ASSOCIATED WITH LOW RHEUMATOID ARTHRITIS ACTIVITY AFTER 3 AND 6 MONTHS

Publikováno v: Annals of the Rheumatic Diseases. 80:1095.3-1096

Background:JAK inhibitors block intracellular signaling pathways responsible for the synthesis of cytokines and mediators involved in the development of chronic pain and central sensitization (CS). This determines a very rapid clinical response to JA

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::77f9af1890928d01dac7b7df61f2fca8
https://doi.org/10.1136/annrheumdis-2021-eular.2902

Zobrazit plný text záznamu

POS1072 ASSOCIATION OF NAIL PSORIASIS WITH WORSE DISEASE OUTCOMES IN PSORIATIC ARTHRITIS PATIENTS. DATA FROM CLINICAL PRACTICE

Autor: N. Kuznetsova, Elena Loginova, E. Gubar, I. Patrikeeva, Svetlana Glukhova, V. Sorotskaya, Irina Umnova, Y. Korsakova, Nasonov El, Alexander Lila, Tatiana Korotaeva

Publikováno v: Annals of the Rheumatic Diseases. 80:815.2-815

Background:Limited data are available regarding the burden of nail disease in psoriatic arthritis (PsA). The latest data show that nail involvement in PsA patients (pts) is associated with significantly more severe disease status (1).Objectives:To an

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f07429054da6550e6284f38965c08135
https://doi.org/10.1136/annrheumdis-2021-eular.1576

Zobrazit plný text záznamu

Autor: O. Fomina, Nasonov El, A. R. Babaeva, A. S. Avdeeva, N. Lapkina, V. Sorotskaya, A Misiyuk, Alexander Lila, A. Satybaldyev

Publikováno v: Annals of the Rheumatic Diseases. 79:1462.3-1463

Objectives:To evaluate the efficacy of tofacitinib therapy (TOFA) in biologic naive and had prior biologic use history patients with rheumatoid arthritis (RA) according to OREL registerMethods:Were analyzed the data from Russian national register of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3c144f94053608a73a832db5379fce33
https://doi.org/10.1136/annrheumdis-2020-eular.3052

Zobrazit plný text záznamu

THU0188 Efficacy and safety of tofacitinib in patients with rheumatoid arthritis who did not respond to synthetic and biological dmards in clinical practice

Autor: E. L. Luchikhina, A. Sizikov, Nasonov El, G. Loukina, O. Ivanova, A. R. Babaeva, D.E. Karateev, Mazurov Vi, A. Baranov, O. Semagina, N. Demidova, L. Evstigneeva, V. Sorotskaya, Diana Abdulganieva, A Misiyuk

Publikováno v: Poster Presentations.

Background Tofacitinib (TOFA) is so far the only representative of a new class of Jak-kinase inhibitors in rheumatology. Despite extensive data on TOFA obtained from 3rd phase studies, for use in clinical practice, the information is limited. Objecti

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::eadc98ea54829e8b6771c3b9686de70d
https://doi.org/10.1136/annrheumdis-2017-eular.5475

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání